

Table 1. Demographic and Treatment Characteristics

Variable	Concomitant Benzodiazepines Subgroup (n=119)	No Concomitant Benzodiazepines Subgroup (n=39)
<i>Baseline demographics</i>		
Female, n (%)	61 (51.3)	24 (61.5)
Age, years, mean (SD)	23.5 (15.0)	23.7 (15.6)
Race, n (%)		
White	99 (83.2)	31 (79.5)
Black/African American	12 (10.1)	3 (7.7)
Other	8 (6.7)	5 (12.8)
<i>Treatment exposure, n (%)</i>		
Duration of exposure		
<6 months	8 (6.7)	3 (7.7)
6 to <12 months	21 (17.6)	10 (25.6)
≥12 months	90 (75.6)	26 (66.7)
Use of ≥2 doses/month	70 (58.8)	19 (48.7)
<i>Seizure episodes treated, n</i>		
Seizure episodes in which a second dose was used, n (%)	3000 286 (9.5)	397 30 (7.6)